PROFILE FOR AEMD.
EARNINGS HISTORY
| 0 MET | Nov, 13, 2024 Actual: -0.2 Estimated: -0.2 |
| +0.1 BEAT | Aug, 14, 2024 Actual: -0.34 Estimated: -0.44 |
| +0.27 BEAT | Jun, 27, 2024 Actual: -0.91 Estimated: -1.18 |
| -0.14 MISS | Feb, 14, 2024 Actual: -1.37 Estimated: -1.23 |
| +0.13 BEAT | Nov, 14, 2023 Actual: -1.22 Estimated: -1.35 |
| -0.1 MISS | Aug, 10, 2023 Actual: -1.3 Estimated: -1.2 |
| +0.5 BEAT | Jun, 28, 2023 Actual: -1.1 Estimated: -1.6 |
| -0.8 MISS | Feb, 13, 2023 Actual: -1.2 Estimated: -0.4 |
NEWS FEED
 | Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu 2024-12-20 08:01:00 SAN DIEGO , Dec. 20, 2024 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza “Bird Flu.” Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu. |  | Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally 2024-11-14 08:00:00 Vancouver, Kelowna, and Delta, British Columbia–(Newsfile Corp. – November 14, 2024) – Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases a snapshot looking at the advancement of treatments for solid tumors as global cancer incidence rates rise, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. According to a recent article in Biospace,”The solid tumors market size reached a value of US$ 170.3 Billion in 2023. |  | Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript 2024-11-13 19:58:02 Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2025Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Michael Miller – Investor Relations, Rx Communications James Frakes – Interim Chief Executive Officer & Chief Financial Officer Steven LaRosa – Chief Medical Officer Conference Call Participants Marla Marin – Zacks Jeremy Pearlman – Maxim Group Operator Good day, and welcome to the Aethlon Medical Fiscal Second Quarter 2025 Earnings and Corporate Update. [Operator Instructions] Please note this event is being recorded. |  | Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update 2024-11-13 16:15:00 Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon’s Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer Trial Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Nov. 13, 2024 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments. |  | Innovative Medical Technology Advances with First Patient Enrollments 2024-11-12 08:00:00 Vancouver, Kelowna, and Delta, British Columbia–(Newsfile Corp. – November 12, 2024) – Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future of medical technology as first patients are enrolled in potential breakthrough trials, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/11120AEMD-First-Patient-Enrollments.asp According to Statista.com, “The Medical Technology market, which encompasses various markets, including Medical Devices, is anticipated to witness significant revenue growth in the coming years. |  | Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia 2024-11-11 08:01:00 Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon’s Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Nov. 11, 2024 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof. |  | Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024 2024-11-06 08:01:00 SAN DIEGO , Nov. 6, 2024 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2024, at 4:15 p.m. ET on Wednesday, November 13, 2024. |  | Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit 2024-10-08 08:01:00 SAN DIEGO , Oct. 8, 2024 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that James Frakes, Chief Executive Officer and Chief Financial Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, hosted by Anthony Vendetti, executive managing director and head of research at Maxim Group, on Tuesday, October 15, 2024 at 4:30 pm ET. To listen to the company presentation, sign up for the conference using this link. |  | Immunotherapy Clinical Trials – A New Approach to Treating Cancer 2024-09-19 10:00:00 Vancouver, Kelowna, and Delta, British Columbia–(Newsfile Corp. – September 19, 2024) – Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of cancer and solid tumors focusing on immunotherapy, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections. Aethlon’s Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer. |  | Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India 2024-09-19 08:01:00 Aethlon Medical Granted Full Ethics Approval from the Medanta Institutional Ethics Committee for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® in Cancer Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Sept. 19, 2024 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that, on September 9, 2024, the Medanta Institutional Ethics Committee (MIEC) granted full ethics approval for Aethlon’s safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). |